Loading...
Loading...
XFOR| Name | Value |
|---|---|
| Revenues | 0.6M |
| Cost of Revenue | 0.5M |
| Gross Profit | 0.1M |
| Operating Expense | 34.0M |
| Operating I/L | -33.9M |
| Other Income/Expense | 124.7M |
| Interest Income | 1.6M |
| Pretax | 90.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 90.8M |
X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company specializing in the research, development, and commercialization of novel therapeutics for rare diseases. Its lead product candidate, mavorixafor, is a small molecule inhibitor of the chemokine receptor CXCR4, currently in Phase III clinical trial for the treatment of patients with specific rare diseases and in Phase Ib clinical trial for other conditions. The company is also developing X4P-002 and X4P-003, both CXCR4 antagonists for the treatment of brain cancers, CXCR4 disorders, and primary immunodeficiencies. Additionally, it has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications.
